Protein design firm Zymeworks in $187M deal with Merck for bi-specific antibodies

 
• By Nancy Faigen

The small private firm Zymeworks, based in Vancouver, British Columbia has struck a major commercialisation deal whereby it will link up its platform technology in bi-specific antibody technology with drug development at Merck & Co in the areas of oncology and autoimmune diseases.

The small private firm Zymeworks, based in Vancouver, British Columbia has struck a major commercialisation deal whereby it will link up its platform technology in bi-specific antibody technology with drug development at Merck & Co in the areas of oncology and autoimmune diseases.

The Canadian firm's proprietary technology – known as the Azymetric platform – is built around the concept of antibodies that consist of two different heavy chains engineered to exclusively assemble into a single molecule,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.